The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.Investors Business Daily • 06/06/25
Amgen's Strategic Path - Navigating Patent Expiries With Promising New TherapiesSeeking Alpha • 06/06/25
Profit From the Silver Tsunami: Must-Watch Senior Care & Aging StocksZacks Investment Research • 06/04/25
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCOCNBC • 06/03/25
Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase IIIZacks Investment Research • 06/03/25
IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTSPRNewsWire • 06/02/25
BetterInvesting™ Magazine Update on Stride Inc. (NYSE: LRN) and Amgen Inc. (NASDAQ: AMGN)PRNewsWire • 05/28/25
The Smartest High-Yielding Dividend Stocks in the Nasdaq Composite Index to Buy With $1,500 Right NowThe Motley Fool • 05/24/25
U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a ResultThe Motley Fool • 05/24/25
Amgen Inc. (AMGN) RBC Capital Markets Global Healthcare Conference (Transcript)Seeking Alpha • 05/21/25
AMGN Down 10% in 3 Months: How to Play the Stock as Tariff Woes LingerZacks Investment Research • 05/21/25
Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects?Zacks Investment Research • 05/19/25
Stock Of The Day: Amgen Slips With Healthcare Sector, But Signals Point To A ReversalBenzinga • 05/15/25
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - YetSeeking Alpha • 05/12/25